OVER 5 YEARS OF PATIENT EXPERIENCE WITH OCREVUS[1,2]

#1 PRESCRIBED DMT FOR MS PATIENTS STARTING OR SWITCHING TO A NEW THERAPY[3*]

More than **1 in 3 MS patients** starting a new therapy start on OCREVUS

2018-2019 New Patient Share[†]



*From July 2017 to April 2019; Symphony Health, rolling 3-month prescriber-based data; includes both naïve and switch patients. Includes all patients with an ICD-10-CM of G35 (multiple sclerosis).
†From January 2018 to March 2019; Symphony Health, average quarterly prescriber-based data. Includes all FDA-approved DMTs for MS as of March 2019. The top 10 DMTs are illustrated as lines in the chart.
‡Each line represents a single MS DMT.
DMT=disease-modifying therapy.

2 YEARS
OF CONTROLLED DATA (PHASE II/III)[1,2]

3+ YEARS
OF OPEN-LABEL EXTENSION DATA[2]

>150K
PATIENTS HAVE BEEN TREATED GLOBALLY[4]

>5,000
US NEUROLOGISTS HAVE PRESCRIBED OCREVUS[5]

No change to the risk-benefit profile since launch[1]

Indications & Important Safety Information

Indications
OCREVUS is indicated for the treatment of:
- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

Contraindications
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.

Warnings and Precautions
Infusion reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.

Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.

Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.

Most Common Adverse Reactions
RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions.

PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.

For additional safety information, please see the accompanying full **Prescribing Information** and **Medication Guide**.

OCREVUS®
ocrelizumab 300MG/10ML INJECTION FOR IV

APPROVED TO TREAT A BROADER RANGE OF MS PATIENTS THAN ANY OTHER APPROVED DMT[1]

Indications

OCREVUS is indicated for the treatment of:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults.

DMT=disease-modifying therapy.

Important Safety Information

Contraindications

OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.

Warnings and Precautions

Infusion reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.

Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.

Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.

Most Common Adverse Reactions

RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions.

PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.

For additional safety information, please see the accompanying full **Prescribing Information** and **Medication Guide**.

References: 1. OCREVUS [prescribing information]. South San Francisco, CA: Genentech, Inc. 2019. **2.** Hauser SL, Brochet B, Montalban X, et al. Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Presented at: 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 10-12, 2018; Berlin, Germany. **3.** Data on file, Symphony Health. Genentech, Inc. April 2019. **4.** Data on file. Genentech, Inc. May 2020. **5.** Data on file. Genentech, Inc. July 2018.

OCREVUS®
ocrelizumab 300MG/10ML INJECTION FOR IV